Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Benjamin Besse, MD, PhD: Expert Insights Into a Neoepitope Vaccine for NSCLC

Posted: Tuesday, October 19, 2021

Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, discusses his work in the Atalante-1 study, describing the nature of the vaccine used, how it works, how well it is tolerated by patients with advanced non–small cell lung cancer, and the potential clinical implications of the study.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.